TNF and COVID-19: In terms of treatments, both registries demonstrated that patients treated with glucocorticoids (GCs) had poor clinical outcomes of COVID‐19, whereas those treated with anti‐TNF therapies, particularly when used as a monotherapy, had a decreased risk of hospitalization due to COVID‐19.10, 11